~~<i id='E98B6A4F8E'><strike id='E98B6A4F8E'><tt id='E98B6A4F8E'><pre id='E98B6A4F8E'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

explore

entertainment

author：fashion 2025-09-28 23:31:12 - browse：387

Michel Pairet -- health business coverage from STAT — Michel Pairet Courtesy Boehringer Ingelheim

LONDON — At an event here last week, the German pharmaceutical firm Boehringer Ingelheim outlined the projects in its pipeline.

There was obesity and liver disease, and computational biology and oncology. Then respiratory and inflammatory diseases. And don’t forget mental illness and retinal health. Oh, it was also the day the company launched another Humira biosimilar.

In other words, there was a whole lot for the company to discuss as it works to promote its breadth and build partnerships with academic researchers and other companies.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
Next article： Twill hunts for pharma partner to market its depression app

hotspot

focus

entertainment

Wikipedia

hotspot

Withthenewprostheticarm,patientscanfeelwhentheyareholdinganobject,andhowhardtheyaregripping,whichise

WSS

UK homeowners get some respite as inflation falls by more than anticipated to a 15

Do more moles mean more problems? Not so, says new study

Biden administration sends mixed signals on US soldier who crossed into North Korea

DeSantis says Trump could've 'come out more forcefully' during Jan. 6

Adam's Biotech Scorecard: Do Sarepta's exon

Stigma and the return of syphilis

explore

entertainment

hotspot

Hepatitis C has a cure — but many Americans still lack access to it

Childbirth

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Startling documents reveal new facets of Sacklers' opioid empire

DIEP, the 'gold standard' of breast reconstruction, is under threat

Scientists successfully use ultrasound imaging to map brain activity

In age of alternative facts, a scholarly course on calling out crap

Merck to buy EyeBio, maker of eye drug, as it grows pipeline

Affirmative action in medical school literally saved lives

Do more moles mean more problems? Not so, says new study

focus

Prosthetic arm enables patients to feel the objects they grip

Antibiotic resistance nearly killed me, so I'm raising awareness of it

Merus drug and Keytruda shrank tumors in patients with head and neck cancer

Startling documents reveal new facets of Sacklers' opioid empire

Startling documents reveal new facets of Sacklers' opioid empire

FDA seeking to stop procedures at two unregulated stem cell clinics

focus

entertainment

Wikipedia

hotspot